Conference Report

Review of Novel Cancer Therapies

Source: CCO Independent Conference Coverage of the 2008 Oncology Nursing Society Annual Congress*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Review of Novel Cancer Therapies

Faculty:

Pamela Hallquist Viale, RN, MS, CS, ANP, AOCNP
Carol S. Viele, RN, MS, CNS, OCN

CME CREDIT INFORMATION

Release Date: 07/30/08

Expiration Date: 07/29/09

Registered Nurses: 0.9 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss recent data from clinical studies of approved and investigational treatments for solid and hematologic malignancies
Describe new insights into optimal nursing intervention and clinical management strategies to enhance patient quality of life
Summarize clinical advances with targeted therapies alone or in combination to treat multiple tumor types

Topics covered include:

Introduction
Novel Treatment Options in Oncology: Bevacizumab, Ixabepilone, and Everolimus
Casopitant: A New Neurokinin-1 Antagonist for Prevention of Chemotherapy-Induced Nausea and Vomiting
Updates in Multiple Myeloma
Safety Profile of Panitumumab Monotherapy in Metastatic Colorectal Cancer
Management of Skin Toxicities
Adverse Events Associated With Ipilimumab in Patients With Advanced Melanoma
Current Topics in Chemotherapy Safety: Vincristine Administration
New Warnings and Restrictions on the Use of Erythropoiesis-Stimulating Agents
Management of Neuropathic Pain
Impact of Genetics and Genomics on Oncology Nursing Practice
Molecular Profiling for Determining Cancer Risk and Its Role in Convergence Therapy
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.